2017
2016
蓝海资本旗下杭州蓝海有方成长有限合伙企业和中信金石旗下青岛灏纳投资有限公司共同参与新三板挂牌公司北京美中嘉和医院管理股份有限公司第二次定向增发。

蓝海资本定增投资美中嘉和医疗5000万元

2016年11月3日,蓝海资本旗下杭州蓝海有方成长有限合伙企业(以下简称“蓝海成长基金”)和中信金石旗下青岛金石灏汭投资有限公司(以下简称“金石灏纳”)共同参与新三板挂牌公司北京美中嘉和医院管理股份有限公司(代码:835660, 以下简称“美中嘉和”)第二次定向增发。本次定增募资以每股15.00元发行,其中蓝海成长基金和金石灏纳分别投资人民币约5000万元,合计投资人民币约1亿元,用于收购母公司资产和二级肿瘤医院发展。

这是蓝海资本与泰和诚集团的大股东Morgancreek Investment Holdings Limited于2016年7月11日宣布以5.19美元的每股价格联合私有化之后,再次直接投资旗下核心子公司。对此,蓝海资本创始合伙人兼CEO杨锋先生评论:“泰和诚集团是中国肿瘤影像诊断及治疗的领先企业,我们对集团优势和管理层有充分信心;美中嘉和是泰和诚集团主营肿瘤影像诊断及放射治疗中心和肿瘤放疗二级医院的核心企业,具有很大发展潜力和长期投资价值”。泰和诚集团兼美中嘉和董事长杨建宇博士认为:“蓝海资本在医疗投资、跨境并购和融资等方面具有丰富经验,在集团和子公司层面分别进行投资,体现了对泰和诚集团的高度认可,我相信在蓝海资本和其他各方投资者的支持下,泰和诚集团继续深入与美国M.D.安德森肿瘤医院全面合作,将促进美中嘉和业务的长足发展,进一步加强在肿瘤诊断和放射治疗方面的领先优势。”

关于美中嘉和:美中嘉和是纽交所上市公司泰和诚医疗(NYSE:CCM)的核心子公司。美中嘉和一直专注于肿瘤影像诊断及放射治疗领域的管理服务,积累了国内外大量的肿瘤诊疗领域的医疗专家资源,公司直接或间接管理着100余家肿瘤诊疗中心,业务覆盖全国几十个城市。美中嘉和正在通过建立自有品牌的肿瘤放疗医院升级已有的肿瘤诊疗网络,凭借多年在肿瘤放射性治疗和影像诊断中心的管理服务经验,选配性能最佳的影像诊断和放射治疗设备、引进和利用国内外最先进的技术和研究成果、采用真正的“人文关怀”服务理念,为肿瘤患者提供优质的服务和精准的治疗。

关于蓝海资本:蓝海资本专注医药健康等领域的并购投资,管理超过4亿美元等值的人民币和美元双币种基金。创始核心团队在医疗健康领域投资、跨境并购和国内外资本市场具有丰富经验。蓝海资本作为独家投资者支持金卫医疗对中国脐带血库企业集团的私有化投资,直接投资2.5亿美元。2016年7月11日,蓝海资本与泰和诚医疗的大股东Morgancreek Investment Holdings Limited宣布以5.19美元每股的价格共同私有化泰和诚。

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

On November 3, 2016, Hangzhou Blue Ocean Youfang Growth Limited Partnership (hereinafter referred to as “Blue Ocean Growth Fund"), a subsidiary fund under Blue Ocean Capital Group (hereinafter referred to as “BOCG”), and Qingdao Goldstone Haorui Investment Co. Ltd. (hereinafter referred to as “Goldstone Haorui”), a subsidiary fund of CITIC Goldstone, jointly participated in the second discretional issuance of Beijing Meizhong Jiahe Hospital Management Corp. Ltd (code: 835660, hereinafter referred to as  “Jiahe”), a public company listed on the Chinese New Third Board. The private offering of additional shares was issued at RMB15.00 per share, and raised about RMB50 million from Blue Ocean Growth Fund and Goldstone Haorui, respectively. In total, the investment amounted to about RMB100 million, which will be used to acquire assets from the parent company and develop secondary cancer hospitals.

Blue Ocean Capital led the new investment into the core subsidiary of Concord Medical Services Holdings Limited (hereinafter referred to as “CCM"), following their announcement of the joint privatization of CCM together with CCM’s main shareholder Morgancreek Investment Holdings Limited, at the price of USD5.19 per share on July 11, 2016.

Frank Yang, founder and CEO of BOCG has the comment:, “CCM is a leading company in cancer imaging diagnosis and treatment in China. We are confident about its expertise and management team. Jiahe is the core business unit of the cancer imaging diagnostics and radiotherapy centers and secondary cancer radiotherapy hospitals of CCM. It has great growth potentials and value for long-term investment.”

Dr. Yang Jianyu, Chairman of CCM and Jiahe, has the comment:, “Blue Ocean Capital has extensive experience in healthcare investment, cross-border M&A and financing, etc. Their investment in CCM and the subsidiary of CCM shows their trust of CCM as a whole. I am sure that with the support of Blue Ocean Capital and other investors, CCM will strengthen the cooperation with MD Anderson Cancer Center in the U.S. and  enhance CCM’s competitive advantages in cancer diagnostics and radiotherapy in the future.”

About Jiahe: Iiahe is the core subsidiary of Concord Medical Services Holdings Limited (NYSE: CCM). It has been specialized in the management of cancer imaging diagnostics and radiotherapy centers, and has gathered a large number of domestic and foreign medical experts in the field of cancer diagnostics and treatment. Now the company is generally managing more than 100 cancer centers, and has expanded its businesses to dozens of cities across China. At present, Jiahe is committed to upgrading the existing cancer treatment network through the establishment of cancer radiotherapy hospitals with its own brand. With twenty years of experience in the management of cancer radiotherapy and imaging diagnostic centers, it has installed the best imaging diagnostic and radiotherapy equipments, brought in the most advanced domestic and foreign technologies and research findings. Meanwhile, Jiahe provides medical services of high quality and precision treatment to cancer patients with “humanistic care” in the culture.

About Blue Ocean Capital: BOCG is specialized in M&A in the pharmaceutical and healthcare sectors. It manages dual currency funds worth more than US$ 400 million in RMB and USD. The core founding team has a wealth of experience in healthcare investment, cross-border M&A among domestic and foreign capital markets. Blue Ocean Capital was the exclusive investor with a direct investment of USD250 million to privatize the China Cord Blood Corporation hold by Golden Meditech. On July 11, 2016, Blue Ocean Capital and Morgancreek Investment Holdings Limited, the major shareholder of CCM, announced a joint privatization of CCM at the price of USD 5.19 per share.